Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983812 | 0.81 | ACHE (0.51) | ACHEOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2905814 | 0.80 | CYP2D6 (0.52) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL7275198 | 0.80 | ACHE (0.46) | ACHEOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL72466 | 0.79 | OPRM1 (0.48) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| Hydrochloric Acid SCHEMBL10506432 | 0.78 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| Hydrochloric Acid SCHEMBL10401309 | 0.78 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL7446995 | 0.76 | OPRD1 (0.49) | ACHEOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3334711 | 0.72 | ACHE (0.50) | ACHEOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL14280201 | 0.71 | ACHE (0.71) | ACHEOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL6774627 | 0.71 | OPRM1 (0.48) | OPRM1OPRD1OPRK1OPRL1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | claimed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | claimed |
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | TRPV1, UTS2R, OPRL1 | ACHE 474/4885OPRM1 5/4885OPRD1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.